Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies

Emerging Research
Written By

The highlights section of this free, full-text European Neuropsychopharmacology article comments:

  • Resistant patients mostly respond to higher dose of psilocybin (ED95: 40 mg/70 kg).
  • The near maximal effective dose was much lower for secondary depression than for primary depression (ED95: 8.92 and 24.68 mg/70 kg respectively).
  • Patients with comorbid anxiety may respond better to lower doses of psilocybin for both depressive and anxiety symptoms reduction.
  • Psilocybin is generally well-tolerated, with transient and mild to moderate adverse events such as headache and nausea.
  • In controlled conditions, psychological discomfort during psychedelic trips can occur at higher doses, but panic reactions are easily managed with psychological support.

For more psychedelic news and research, visit the psychedelic health professional network homepage.

Previous

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Next

Addiction specialists' attitudes toward psychedelics: A National Survey